Quanterix Corp

Listed Company

QTRXCIK 0001503274NasdaqAcceleratedLaboratory Analytical InstrumentsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$138.90M

Net Income

$-107.20M

Total Assets

$418.77M

Equity

$295.73M

Shares Out

46.94M

Op. Cash Flow

$-77.24M

Business

Quanterix Corp is a life sciences company that develops and commercializes ultra‑sensitive digital immunoassay platforms based on its proprietary Simoa detection technology for protein biomarker measurement. It offers Simoa instruments (HD‑X, SR‑X, SP‑X, and the developing Simoa ONE), assay kits and consumables, custom and homebrew assay development, sample testing services, and clinical Laboratory Developed Tests under its Lucent Diagnostics brand. Its business is organized around instruments and consumables, assay menu and reagent products (including Nova Beads and Uman NfL antibodies), and laboratory services/diagnostics. Quanterix distributes products worldwide through direct sales, field support, and third‑party distributors across North America, Europe, Asia‑Pacific and other international markets.

Summary from filing dated 2025-03-17

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	139	137	122	106	111
Total costs of goods sold and services	74	54	48	60	49
Gross profit	65	83	74	45	62
Research and development	36	31	26	27	28
Selling, general and administrative	138	102	89	92	92
Other lease costs	844,000	3	4	1	—
Impairment and restructuring	16	0	1	30	0
Total operating expenses	191	136	120	150	120
Loss from operations	−126	−53	−46	−104	−59
Interest income	9	15	16	5	−403,000
Change in fair value of contingent liabilities	−5	0	0	—	—
Other income (expense), net	157,000	−136,000	3	−277,000	1
Loss before income taxes	−112	−38	−28	−99	−58
Income tax benefit (expense)	5	−434,000	−719,000	−164,000	36,000
Net loss	−107	−39	−28	−100	−58
Net loss per common share, basic (in dollars per share)	−2.51	−1	−0.75	−2.69	−1.6
Net loss per share, diluted (in dollars per share)	−2.51	−1	−0.75	−2.69	−1.6
Weighted-average common shares outstanding, basic (in shares)	43	38	38	37	36
Weighted-average common shares outstanding, diluted (in shares)	43	38	38	37	36

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	30	57	174	339	397
Marketable securities	88	232	147	0	—
Accounts receivable, net of allowance for expected credit losses	30	32	25	19	24
Inventory	55	33	26	17	22
Prepaid expenses and other current assets	9	10	9	7	7
Total current assets	212	364	382	381	449
Restricted cash	3	3	3	3	3
Property and equipment, net	24	17	18	20	18
Intangible assets, net	132	4	6	8	11
Goodwill	26	0	—	—	10
Operating lease right-of-use assets	17	16	18	21	11
Other non-current assets	5	3	2	1	378,000
Total assets	419	407	429	434	502
Accounts payable	14	7	5	4	9
Accrued compensation and benefits	15	13	14	11	13
Accrued expenses and other current liabilities	18	9	6	5	—
Deferred revenue	21	9	9	9	6
Operating lease liabilities	8	5	4	3	1
Total current liabilities	75	42	39	31	37
Deferred revenue, net of current portion	6	1	1	1	1
Operating lease liabilities, net of current portion	29	33	37	41	20
Non-current portion of contingent liabilities	5	0	—	—	—
Other non-current liabilities	8	800,000	1	1	2
Total liabilities	123	76	79	75	61
Commitments and contingencies (Note 16)	—	—	—	—	—
Common stock, $0.001 par value per share: Authorized: 120,000 shares; issued and outstanding: 46,744 and 38,573 shares at December 31, 2025 and 2024, respectively	47,000	39,000	38,000	37,000	37,000
Additional paid-in capital	874	803	783	764	746
Accumulated other comprehensive loss	−723,000	−3	−2	−3	441,000
Accumulated deficit	−577	−470	−432	−402	−305
Total stockholders equity	296	330	350	358	443
Total liabilities and stockholders equity	419	407	429	434	502

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−107	−39	−28	−100	−58
Depreciation and amortization expense	16	6	6	5	5
Credit losses on accounts receivable	628,000	588,000	336,000	−301,000	213,000
Accretion of marketable securities	−2	−7	−2	0	—
Operating lease right-of-use asset amortization	3	2	2	715,000	499,000
Stock-based compensation expense	21	20	17	15	16
Impairment	8	0	1	26	—
Recognition of off-market liability	−3	0	0	—	—
Deferred taxes	−6	−290,000	−290,000	−226,000	—
Other operating activity	−540,000	345,000	140,000	−340,000	692,000
Accounts receivable	11	−8	−7	5	−7
Inventory	4	−7	−9	7	−8
Prepaid expenses and other current assets	4	−443,000	−2	−738,000	−393,000
Other non-current assets	252,000	−1	−717,000	−822,000	−2,000
Accounts payable	−528,000	723,000	1	−5	2
Accrued compensation and benefits, accrued expenses, and other current liabilities	−8	1	4	−4	606,000
Net change in other operating assets and liabilities	−12	−5	−2	—	—
Net cash used in operating activities	−77	−35	−19	−49	−48
Purchases of marketable debt securities	−70	−296	−176	0	—
Proceeds from sales and maturities of marketable securities	216	217	31	0	—
Purchases of property and equipment	−3	−3	−4	−12	−14
Acquisitions, net of cash acquired	−93	0	0	—	—
Net cash provided by (used in) investing activities	50	−82	−148	−11	−6
Proceeds from common stock issued under stock plans	738,000	3	3	2	9
Payments for employee taxes withheld on stock-based compensation awards	−1	−3	−198,000	0	—
Net cash provided by (used in) financing activities	−708,000	456,000	3	2	271
Net decrease in cash, cash equivalents, and restricted cash	−28	−117	−165	−57	217
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	2	−734,000	301,000	−538,000	−92,000
Common stock issued in exchange for acquisition of Akoya	50	0	0	—	—
Purchases of property and equipment in accounts payable and accruals	121,000	1	419,000	152,000	229,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro